Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Assets: 2019-2025

Historic Current Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $312.4 million.

  • 4D Molecular Therapeutics' Current Assets fell 38.84% to $312.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.4 million, marking a year-over-year decrease of 38.84%. This contributed to the annual value of $434.9 million for FY2024, which is 46.65% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Current Assets of $312.4 million as of Q3 2025, which was up 3.00% from $303.3 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Current Assets peaked at $552.6 million during Q2 2024, and registered a low of $165.7 million during Q3 2021.
  • Moreover, its 3-year median value for Current Assets was $328.2 million (2023), whereas its average is $375.6 million.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 158.69% in 2024, then slumped by 45.12% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Current Assets stood at $256.3 million in 2021, then dropped by 13.96% to $220.5 million in 2022, then surged by 34.50% to $296.6 million in 2023, then skyrocketed by 46.65% to $434.9 million in 2024, then plummeted by 38.84% to $312.4 million in 2025.
  • Its Current Assets stands at $312.4 million for Q3 2025, versus $303.3 million for Q2 2025 and $332.6 million for Q1 2025.